[go: up one dir, main page]

NO20004251D0 - Humaniserte anti-CEA monoklonale antistoffer med høy affinitet - Google Patents

Humaniserte anti-CEA monoklonale antistoffer med høy affinitet

Info

Publication number
NO20004251D0
NO20004251D0 NO20004251A NO20004251A NO20004251D0 NO 20004251 D0 NO20004251 D0 NO 20004251D0 NO 20004251 A NO20004251 A NO 20004251A NO 20004251 A NO20004251 A NO 20004251A NO 20004251 D0 NO20004251 D0 NO 20004251D0
Authority
NO
Norway
Prior art keywords
monoclonal antibodies
high affinity
humanized anti
affinity monoclonal
cea
Prior art date
Application number
NO20004251A
Other languages
English (en)
Other versions
NO20004251L (no
Inventor
William Henry Kerr Anderson
Philip R Tempest
Frank J Carr
William J Harris
Kathryn Armour
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Publication of NO20004251D0 publication Critical patent/NO20004251D0/no
Publication of NO20004251L publication Critical patent/NO20004251L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007Carcino-embryonic Antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6853Carcino-embryonic antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1048Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • G01N33/57565
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO20004251A 1998-02-25 2000-08-24 Humaniserte anti-CEA monoklonale antistoffer med høy affinitet NO20004251L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/003680 WO1999043817A1 (en) 1998-02-25 1998-02-25 High affinity humanized anti-cea monoclonal antibodies

Publications (2)

Publication Number Publication Date
NO20004251D0 true NO20004251D0 (no) 2000-08-24
NO20004251L NO20004251L (no) 2000-10-24

Family

ID=22266464

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004251A NO20004251L (no) 1998-02-25 2000-08-24 Humaniserte anti-CEA monoklonale antistoffer med høy affinitet

Country Status (7)

Country Link
EP (1) EP1056859A1 (no)
JP (1) JP2002504372A (no)
AU (1) AU752494B2 (no)
CA (1) CA2321947A1 (no)
IL (1) IL138022A0 (no)
NO (1) NO20004251L (no)
WO (1) WO1999043817A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003025565A2 (en) * 2001-09-21 2003-03-27 Caprion Pharmaceuticals Inc. Preparation of highly-purified plasma membranes
KR20130114758A (ko) * 2005-05-27 2013-10-17 오스페달레 산 라파엘 에스.알.엘. Mi-rna를 포함하는 유전자 벡터
MY164647A (en) * 2011-03-02 2018-01-30 Roche Glycart Ag Cea antibodies
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CN106749667B (zh) * 2016-12-04 2020-07-14 深圳市国创纳米抗体技术有限公司 一种抗癌胚抗原的纳米抗体及其应用
CN113906053B (zh) 2019-06-26 2022-10-25 江苏恒瑞医药股份有限公司 抗cea抗体及其应用
CN116724052A (zh) 2020-08-20 2023-09-08 A2生物治疗股份有限公司 用于治疗ceacam阳性癌症的组合物和方法
KR20250140123A (ko) 2020-08-20 2025-09-24 에이투 바이오쎄라퓨틱스, 인크. 메소텔린 양성 암을 치료하기 위한 조성물 및 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5472693A (en) * 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
WO1997042329A1 (en) * 1996-05-04 1997-11-13 Zeneca Limited Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system

Also Published As

Publication number Publication date
NO20004251L (no) 2000-10-24
AU6338898A (en) 1999-09-15
AU752494B2 (en) 2002-09-19
EP1056859A1 (en) 2000-12-06
WO1999043817A1 (en) 1999-09-02
IL138022A0 (en) 2001-10-31
CA2321947A1 (en) 1999-09-02
JP2002504372A (ja) 2002-02-12

Similar Documents

Publication Publication Date Title
DE69920897D1 (de) Monoklonale antikörper mit verringerter immunisierungsfähigkeit
DK1516629T3 (da) Humaniseret anti-CD-11a antibodies
PT719859E (pt) Anticorpo monoclonal anti-alfa v-integrina
FI963004L (fi) Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita
FI964845L (fi) CD44v6:n vastaiset monoklonaaliset vasta-aineet
EP1071458A4 (en) HUMANIZED ANTIBODIES AND CORRESPONDING USES THEREOF
HUP0300841A3 (en) Agonist anti-trk-c monoclonal antibodies
AU2559799A (en) Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same
DE69828154D1 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
DE69738312D1 (de) Hepatitis b monoklonale antikörper
FI945865A7 (fi) Glykoprofeiini P:lle kohdistettuja monoklonaalisia vasta-aineita
AU7072998A (en) Immunoassays using anti-allotypic monoclonal antibodies
NO20004251D0 (no) Humaniserte anti-CEA monoklonale antistoffer med høy affinitet
NO981272D0 (no) Humanisert anti-human-Fas-antistoff
GB9718911D0 (en) Monoclonal antibodies
FI20011055A0 (fi) Heveiiniä sitovat monoklonaaliset vasta-aineet
EP1106701A4 (en) MONOCLONAL ANTIBODY DIRECTED AGAINST DYNAMIC TRYPSIN
NO985281D0 (no) Monoklonalt antihumant MP52-antistoff
BR1100555B1 (pt) anticorpos monoclonais humanizados.
ZA99319B (en) Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same.
AU2002300457A1 (en) Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies
GB9615027D0 (en) Monoclonal antibodies
IL125204A0 (en) Anti-bacterial monoclonal antibodies
SI0742795T1 (en) Immuno-stimulatory monoclonal antibodies
GB0003359D0 (en) Monoclonal antibodies

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application